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Abstract
We previously reported that mutation of galE in Porphyromonas gingivalis has pleiotropic effects, including a truncated
lipopolysaccharide (LPS) O-antigen and deglycosylation of the outer membrane protein OMP85 homolog. In the present
study, further analysis of the galE mutant revealed that it produced little or no outer membrane vesicles (OMVs). Using three
mouse antisera raised against whole cells of the P. gingivalis wild type strain, we performed ELISAs to examine the reactivity
of these antisera with whole cells of the wild type or the galE mutant. All three antisera had significantly lower reactivity
against the galE mutant compared to wild type. OMVs, but not LPS, retained the immunodominant determinant of P.
gingivalis, as determined by ELISAs (with wild type LPS or OMVs as antigen) and absorption assays. In addition, we assessed
the capacity of OMVs as a vaccine antigen by intranasal immunization to BALB/c mice. Synthetic double-stranded RNA
polyriboinosinic polyribocytidylic acid [Poly (I:C)], an agonist of Toll-like receptor 3 (TLR3), was used as the mucosal adjuvant.
Vaccination with OMV elicited dramatically high levels of P. gingivalis-specific IgA in nasal washes and saliva, as well as
serum IgG and IgA. In conclusion, the OMVs of P. gingivalis have an important role in mucosal immunogenicity as well as in
antigenicity. We propose that P. gingivalis OMV is an intriguing immunogen for development of a periodontal disease
vaccine.
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Introduction
Periodontitis is an oral disease characterized by destruction of
periodontal tissues and ultimately exfoliation of the teeth in
humans [1]. In addition, recent reports from epidemiological
studies [2,3,4] as well as in vitro and animal model experiments
[5,6,7] have shown an association between periodontitis and
systemic diseases such as diabetes mellitus, cardiovascular disease,
and atherosclerosis. Therefore, development of a safe vaccine for
periodontal diseases would be a great benefit to improving public
health. Among the various Gram-negative anaerobes that reside
within the subgingival pockets, Porphyromonas gingivalis is a major
causative agent in the initiation and progression of severe forms of
periodontal disease [1]. Several virulence factors of P. gingivalis are
known, including fimbriae, gingipains, hemagglutinins, lipopoly-
saccharide (LPS), and outer membrane vesicles (OMVs) [1].
However, it is not known that P. gingivalis components are targeted
by the protective humoral immune system during disease onset
and progression.
Gram-negative bacteria are distinguished from other prokary-
otes by an outer membrane that surrounds their peptidoglycan
layer. The outer membrane contains essential molecules, such as
LPS and outer membrane proteins [8]. Of particular medical
interest are the miscellaneous surface-exposed molecules on intact
bacteria that are recognized by the immune system and possess a
powerful potential to activate the host immune system. Gram-
negative bacteria release OMVs from the cell surface during
bacterial growth [9]. OMVs range in size from 20 to 250 nm in
diameter and contain not only components of the outer mem-
brane, such as LPS, outer membrane proteins, and phospholipids,
but also periplasmic proteins and cell wall components, i.e.,
peptidoglycan, given that OMVs entrap some of the underlying
periplasmic proteins and small particles of the cell wall when the
blebs are extruded from the cell surface. OMVs play a role in such
pathogenic processes as toxin export [10,11,12] and adherence to
eukaryotic cells [13]. As with OMVs of other bacteria, P. gingivalis
OMVs contain several virulence factors, such as LPS, fimbriae,
and gingipains [14,15,16,17]. Recently, P. gingivalis has been
shown to possess a system that selectively sorts virulence factors
into OMVs [18]. OMVs of P. gingivalis also can be internalized
into host cells via a lipid-raft-dependent endocytic pathway and
are subsequently routed to the early endosome followed by sorting
into lysosomal compartments [19]. After lysis of the OMV, various
antigens may be recognized and processed by antigen-presenting
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of adaptive immunity including pathogen-specific antibody
production.
OMVs have also been recognized as a vaccine candidate for
infectious diseases. In several countries, wild type OMVs of
Neisseria meningitidis serogroup B were approved as vaccines for
parenteral use with reported efficacy rates of 70% to 83% in adults
and children [20]. Currently, OMV vaccines are the only
formulation that have shown efficacy against serogroup B
meningococcal diseases. Intranasal administration of OMVs
derived from Vibrio cholerae has also induced protective immunity
against this gastrointestinal pathogen in mice [21]. In the case of P.
gingivalis, although parenteral administration of OMVs in mice is
protective against challenge infection [22], the efficacy of OMVs
as an intranasal vaccine has not yet been determined.
In the present study, we identified an OMV-negative mutant of
P. gingivalis and investigated its antigenicity by comparative analysis
with the wild type strain. Our results indicated that OMVs play a
significant role in the antigenicity of P. gingivalis. In addition, we
demonstrated that intranasal administration of P. gingivalis OMVs
effectively elicited not only serum IgG and IgA, but also secretory
IgA (s-IgA) in nasal washes and saliva that recognize P. gingivalis.
Materials and Methods
Bacterial strains and culture conditions
P. gingivalis ATCC 33277 and the galE mutant [23] were
maintained in brain heart infusion (BHI) broth supplemented with
hemin and menadione (HM) or on BHI-HM blood agar plates in
an anaerobic chamber (miniMACS anaerobic workstation, Don
Whitley Scientific Ltd., Shipley, UK) using 80% N2, 10% H2, and
10% CO2.
Preparation of OMVs and LPS from P. gingivalis
Preparation of OMV was performed as described previously
with some modifications [11]. In brief, the supernatant of a two-
day culture of strain 33277 was collected by centrifugation at
3,4106 g for 15 min at 4uC, then filtered through a 0.22-mm
PVDF filter and ultra-centrifuged at 100,0006g for three hours at
4uC in a 41 Ti rotor (Beckman Instruments, Inc., USA). The
resulting OMV pellet was resuspended in 20 mM Tris-Cl (pH 8.0)
and the protein concentration was measured by Bradford assay
[24] using bovine serum albumin as a standard. Preparation of
LPS from P. gingivalis was performed using the hot phenol water
extraction method with some modifications [23]. Finally, LPS was
lyophilized, weighed and used for mitogenic assays or ELISAs.
Mitogenic assays
The mitogenic activity of LPS prepared from the wild type and
the galE mutant was assessed by adding various concentrations of
LPS (0.1–100 mg/ml) to primary splenocyyte cultures (5610
5
cells/ml) prepared from BALB/c mice. A proliferation assay using
WST-1 (Dojindo Laboratories, Kumamoto, Japan) was then
performed.
Scanning electron microscopy (SEM)
To analyze cell morphology, P. gingivalis wild type or the galE
mutant strain were grown on non-treated plastic sheets (Wako
Chemical Ltd., Osaka, Japan) placed in 6-well polystyrene cell
culture plates. Four 610
7 CFU of P. gingivalis were grown in two
ml of BHI-HM broth per well at 37uC for 12 hours under
anaerobic conditions. For analysis of OMVs derived from P.
gingivalis, the bacterial supernatant was collected at different time
points, then incubated on poly L-lysine-coated cover slips for
30 min at room temperature to attach the OMVs to the glass. The
attached bacteria and OMVs were fixed with 2.5% glutaraldehyde
and 2% paraformaldehyde in PBS for 30 min at room
temperature, followed by three washes in PBS. The samples were
washed in PBS; dehydrated in 50% ethanol to absolute ethanol;
immersed in isoamyl acetate; dried by critical point drying; coated
with osmium vapor using an osmium plasma coater; and
visualized by SEM (S-5200, HITACHI, Hitachi, Japan).
Time-course analysis of bacterial growth and LPS in the
supernatant
Growth assays were performed by measuring OD600. The
bacterial supernatant was collected by centrifugation at 17,4006g
for two minutes at different time points. The amount of LPS in the
supernatant was measured by Limulus amoebocyte lysate (LAL)
reagent according to the manufacturer’s instructions (Seikagaku
Corporation, Tokyo, Japan).
Immunization
All animal experiments were performed in accordance with our
institutional guidelines. Female BALB/c mice (Japan SLC, Inc.,
Hamamatsu, Japan), aged 6 to 8 weeks at the time of
immunization, were used in all experiments. For the first half of
the experimental plan, the mice were immunized by the
conventional method to obtain P. gingivalis-specific antisera as
follows: 1610
8 CFU of heat-killed bacteria emulsified in TiterMax
Gold (TiterMax USA; Norcross, GA) was injected into mice
intraperitoneally followed by two booster injections on days 8 and
15 with 5610
7 CFU of heat-killed bacteria in incomplete Freund’s
adjuvant. For the second half of the experimental plan, the mice
were immunized intranasally. In brief, mice were immunized by
dropping 5 ml of PBS containing 5 mg of polyriboinosinic
polyribocytidylic acid [Poly (I:C)] (Sigma, St. Louis, MO) with
or without 0.5 mg of immunogen (OMVs or heat-killed whole cells
of P. gingivalis ATCC 33277) into each nostril on day 0 and week 3
under anesthesia. The protein concentration of these immunogens
was determined by Bradford assay [24]. At two weeks after the
second immunization, sera, nasal washes, and saliva specimens
were collected and used for ELISA. Saliva samples were obtained
as described previously [25].
ELISA
Reactivities of mouse sera and nasal washes with whole cells of
the bacterial strains were tested using an ELISA described
previously with some modifications [26]. Unwashed whole cells
of P. gingivalis were prepared from fresh bacterial culture by
centrifuging only once at 3,4106g for 15 minutes at 4uC without
washing. For washed whole cells, bacteria were collected by
centrifugation and resuspended in PBS by pipetting. The centri-
fugation and washing steps were repeated. Both the unwashed and
washed bacteria were collected and freeze-dried. The dried
bacteria were weighed and used as antigen for whole-cell ELISA.
ELISA plates were coated with 10 mg of the freeze-dried bacteria
resuspended in 100 ml of ELISA coating buffer per well. After
overnight blocking at 4uC with 1% skim milk in PBS with 0.5%
Tween 20 (PBS-T), each serum or nasal wash sample was serially
diluted with 1% skim milk in PBS-T, added to the wells and
incubated for 1 hour at 37uC. The wells were then incubated for
1 hour at 37uC with alkaline phosphatase-conjugated goat anti-
mouse IgG, IgA, and IgM (Invitrogen, Carlsbad, CA) at a dilution
of 1:1000. Subsequently, P. gingivalis-specific antibody was detected
by chromogenic development using para-nitrophenyl phosphate as
the alkaline phosphatase substrate. Absorbance at OD405 was
Mucosal Immunogenicity of Outer Membrane Vesicles
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and 2 hours. The titer of each antiserum recognizing LPS and
OMV from P. gingivalis 33277 was determined using the same
ELISA protocol, except the microtiter wells were initially coated
with antigen at 100 ng/well. In the absorption assay, each serum
sample was diluted at 1:1000 in PBS and pre-incubated with
10 ng/ml of LPS or OMV purified from strain 33277 for 1 hour
at 37uC. Then, the absorbed serum samples were passed through a
Detoxigel
TM (Thermo Fisher Scientific, Waltham, MA) column
twice to remove possible contaminant LPS and LPS-associated
molecules. An LAL assay was performed to confirm that the serum
did not contain any detectable LPS. The purified sera were used
for ELISA.
Statistical analysis
Statistical analysis was performed using the Mann-Whitney’s U-
test. P-values of 0.05 or less were considered to be statistically
significant.
Results
P .gingivalis galE mutant essentially lacks OMVs as well as
LPS in the supernatant
We previously demonstrated that mutation of the galE gene in P.
gingivalis caused pleiotropic effects associated with the metabolic
pathway of galactose, resulting in autoaggregation/biofilm forma-
tion as well as deglycosylation of LPS and the outer membrane
protein Omp85 homolog [23,27]. Notably, galE mutation also
affects components of the outer membrane, therefore we
hypothesized that morphological changes might occur at the
bacterial surface of the galE mutant.
Firstly, we examined the morphology of wild type and the galE
mutant using scanning electron microscopy (SEM). There was no
difference in the size or shape of mutant cells compared to wild
type (Fig. 1A). On the surface of the wild type cells, many OMVs
were clearly visible as spherical structures approximately 50–
70 nm in diameter (Fig. 1A). However, we could not find any
OMVs on the surface of the galE mutant (Fig. 1A). We also
analyzed by SEM the OMVs discharged into the bacterial
supernatant at different time points during three days of culture
(Fig. 1B). The numbers of OMVs in the supernatant of the wild
type strain increased until day 3 (Fig. 1B). In contrast, we could not
find any OMVs in the supernatant of the galE mutant throughout
the three days (Fig. 1B). To test whether the galE mutant also
releases less LPS during culture, we examined the kinetics of the
LPS activity in the supernatants of the wild type and galE mutant
by LAL assay (Fig. 1C) with their growth curves (Fig. 1D). The
Limulus activity in the supernatant of the wild type increased
through day 3. In contrast, the Limulus activity in the galE mutant
supernatant increased minimally during the same time period,
remaining similar to that of sterile BHI-HM liquid media
(7.54 EU/ml) shown by an arrow in Fig. 1C. To evaluate LPS
quality, we compared LPS prepared from the wild type and the
galE mutant in a mitogenic assay. The mitogenic assay showed that
LPS from both strains had similar activities (data not shown),
suggesting that the lower Limulus activity of galE mutant
supernatant compared to wild type (Fig. 1C) is due to less total
LPS, not lower LPS activity.
Figure 1. SEM images of P. gingivalis wild type and the galE mutant. (A) P. gingivalis wild type and galE mutant were grown on plastic sheets
for 12 hours. Upper panels show the morphology of the attached cells. The lower panels, enlargements of the squares in the upper panels, show the
presence and absence of OMVs on wild type and galE mutant cells, respectively. The scale is shown at the lower right of each electron micrograph. (B,
C, and D) OMVs of wild type and the galE mutant were harvested at different time points during culture. (B) The OMVs were applied to plastic sheets,
and visualized by SEM. The scale is shown at the lower right. The limulus activity (C) and growth (D) of each sample were recorded.
doi:10.1371/journal.pone.0026163.g001
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determinants
We next examined whether OMVs function as a reservoir of
immunoreactive antigens. We performed whole-cell ELISA to test
the reactivity of preimmune serum and three mouse antisera
(raised against whole P. gingivalis wild type by conventional
immunization) to the wild type and galE mutant. All three antisera
showed a significantly higher reaction to unwashed wild type than
to unwashed galE mutant (asterisk-1 in Fig. 2), while background
reactivity of preimmune serum to the wild type and galE mutant
were comparable, irrespective of washing. All antisera showed
significantly lower reactivities to both washed wild type and the
washed galE mutant, compared to when the corresponding
bacteria without washing served as ELISA antigen (asterisk-2
and -3 in Fig. 2). Washing resulted in a larger decrease in antisera
reactivity for the wild type (asterisk-2 in Fig. 2) than for the galE
mutant (asterisk-3 in Fig. 2), indicating that cell washing drastically
reduced surface antigenicity due to loss of OMVs and probably
other bacterial appendages as well. When washed cells were used
as antigen, two of the three antisera, antiserum-1 and -3, had
significantly stronger reactivity to the galE mutant than to the wild
type (asterisk-4 in Fig. 2). It is possible that the galE mutant is more
antigenic than the wild type, because antigenic determinants on
the outer membrane of the galE mutant may be more readily
exposed to the environment by deglycosylation of LPS [23] and/
or outer membrane glycoproteins [27].
In Figure 2, we showed that OMVs associated with bacteria
enhanced antigenicity. However, LPS may also play a key role in
eliciting antibody production and therefore may affect the
antigenicity of Gram-negative bacteria. To determine whether
LPS and/or OMVs are involved in antigenicity, we examined the
reactivity of mouse serum IgG to LPS and OMVs using
preimmune serum and one of three antisera against P. gingivalis
that showed reactivity to the whole cells, antiserum-2 (Fig. 2). The
reactivity of preimmune serum against OMV or LPS was low
(Fig. 3A). Antiserum-2 reacted strongly to OMV, but not to LPS
(Fig. 3A).
To provide further confirmation, we performed an absorption
assay where specific antibodies were absorbed from the sera before
ELISA. To remove LPS- or OMV- specific antibodies, the sera
were absorbed by pre-incubation with LPS or OMV. The
reactivity of antiserum-2 to whole P. gingivalis cells decreased
significantly after pre-incubation with OMV in comparison to pre-
incubation with PBS (Fig. 3B). However, pre-incubation with LPS
did not influence the reactivity of the antiserum-2 against P.
gingivalis (Fig. 3B). We also obtained similar results obtained by
absorption assay using the other antisera (antiserum-1 and -3).
OMVs of P. gingivalis elicit P. gingvalis-specific humoral
immune responses
To investigate whether OMVs have the potential to induce not
only antibodies in blood, but also mucosal antibodies that recognize
P. gingivalis in mice, we designed an intranasal immunization
protocol using OMVs and a mucosal adjuvant (Fig. 4A). Double-
stranded RNA has been shown to be an effective adjuvant for
mucosal vaccination against influenza virus [28,29]. Therefore, we
chose Poly (I:C), a double-stranded RNA adjuvant, as our vaccine
adjuvant. Briefly, after intranasal immunization of OMVs or whole-
cell P. gingivalis twice on day 0 and day 21, mice were sacrificed at
week five, and Ig titers were determined by whole cell ELISA.
Intranasal immunization with P. gingivalis whole cells did not
effectively induce P. gingivalis-specific antibodies (Fig. 4B–E). In
contrast, immunization with OMVs strongly induced P. gingivalis-
antibodies in mice(Fig. 4B, C, and E). Notably, OMVs also strongly
induced nasal wash IgA, as well as serum IgG and IgA. As with the
nasal wash, we also observed strong induction of saliva IgA in mice
immunized with OMVs (Fig. 4F), but not in either sham-
immunized (PBS) (Fig. 4F) or pre-immune mice (data not shown).
P. gingivalis-specific serum IgM was not found due to similar
reactivity among all mouse groups (Fig. 4D).
Figure 2. Analysis of antigenicity of whole cells from wild type and the galE mutant using P. gingivalis antisera. ELISA plates were
coated with freeze-fried P. gingivalis wild type or the galE mutant. Bacteria were either washed twice with PBS or left unwashed before coating. P.
gingivalis antisera from three different mice and a pre-immune serum were used at dilutions of 1:1,000. Sera reactivity was determined as the
absorbance at 405 nm (mean 6 SD) for triplicate assays after a 30-min incubation with alkaline phosphatase substrate. Asterisks-1, -2, -3, and -4
denote statistically significant differences (p,0.05).
doi:10.1371/journal.pone.0026163.g002
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In Fig. 1A and B, we demonstrated that OMVs were not
detectable in the galE mutant. Growth of the galE mutant was
similar to that of the wild type (Fig. 1D), however, the limulus
activity of the respective supernatants was quite different. The
limulus activity of the wild type strain supernatant increased
steadily through culture day 3, while that of the galE mutant
remained similar to baseline (Fig. 1C). These data suggest that
OMV probably plays an important role in dissemination of LPS to
the external environment during growth. However, since galE
mutation causes pleiotropic effects [23,27], it is also possible that
changes in OMV formation and LPS release are two unrelated
events in this mutant.
WhenwashedbacterialcellswereusedasantigenforELISA,allP.
gingivalis antisera exhibited drastically decreased reactivity to the wild
type (asterisk-2 in Fig. 2), but only mildly decreased reactivity to the
galE mutant (asterisk-3 in Fig. 2). P. gingivalis antiserum recognized
OMV, but not LPS (Fig. 3A). Absorption assays revealed that P.
gingivalis antiserum reactivity to whole bacteria decreased after pre-
incubation with OMVs (Fig. 3B). Our data suggest that OMVs play
a pivotal role in the antigenicity of P. gingivalis and other appendages
loosely tethered to the outer membrane, such as fimbriae may also
affect the antigenicity of P. gingivalis.
The presence of OMVs on P. gingivalis (Fig. 1A) may confer
increased antigenicity simply because the vesicles effectively
expand the bacterial surface area. On the other hand, surprisingly,
P. gingivalis-specific antibody was not detectable when mice were
immunized with whole P. gingivalis cells, while OMV immunization
strongly elicited specific antibodies (Fig. 4). Therefore, an
alternative reason that both antigenicity and immunogenicity
were enhanced by the presence of OMVs might be that
immunodominant determinants are more concentrated on OMVs
than on the bacterial surface itself. Many reports have shown that
virulence factors are associated with OMVs in Gram-negative
bacteria (reviewed by [30]), including P. gingivalis [14,15,16,17,18].
Thus, we suggest that our strategy of OMV vaccination via the
nasal cavity might be applicable to P. gingivalis bacterial infections
whose virulence factors are enriched in the OMV.
Double-stranded RNA, such as the Poly (I:C) and AmpligenH,
is a Toll-like receptor 3 (TLR3) agonist. Promising results have
been obtained using Poly(I:C) or AmpligenH as an adjuvant in
flu vaccine delivered intranasally to mice [28,29]. The safety of
AmpligenH also has been established in clinical trials for patients
with chronic fatigue syndrome in the U.S. [31]. On the other
hand, in many animal studies cholera toxin (CT) B subunit or
the mutant CTB [32] has been used as a strong adjuvant to
induce protective immunity. However, use of heat-labile
Figure 3. P. gingivalis antiserum cross-reacts strongly with OMVs, but not with LPS. (A) ELISA plates were coated with LPS and OMVs of P.
gingivalis. P. gingivalis, antiserum-2 and pre-immune serum were used at dilutions of 1:1,000. Sera reactivity was determined as the absorbance at
405 nm (mean 6 SD) for triplicate assays after a 30-min incubation with alkaline phosphatase substrate. (B) To test whether antiserum-2 cross-reacts
with OMVs or LPS, we absorbed the serum against LPS and OMVs and removed bound antibodies. ELISA results are expressed as absorbance at
405 nm (mean 6 SD) after a 30-min incubation with alkaline phosphatase substrate.
doi:10.1371/journal.pone.0026163.g003
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to CT, has been linked to severe complications, such as several
cases of Bell’s palsy (facial paralysis) [33]. Therefore, at present,
an adjuvant derived from a toxin is impractical for use in a
human vaccine, especially for periodontal disease vaccine,
because the benefit of the vaccine must far outweigh the risk
of serious side effects.
In this study, we applied Poly (I:C) as an adjuvant for OMV
intranasal immunization of mice. Without using a toxin-derived
adjuvant, we successfully elicited an s-IgA response in saliva as well
as a serum IgG response. In periodontal pockets, periodontopathic
bacteria float as planktonic cells or form biofilms in the fluid
composed of gingival cervicular fluid (GCF) and saliva. While the
GCF contains abundant immunoglobulins (mostly IgG) exuding
from blood vessels, the saliva contains abundant s-IgA. Therefore,
both the systemic and mucosal immune responses contribute to
humoral immunity in the oral cavity and are important in the
context of a vaccine strategy against periodontal diseases. In
particular, s-IgA is regarded as a main player in immunological
defense at the mucosal surface because pathogen-specific s-IgA can
inactivate the pathogen before it invades the host. In addition, s-
IgA is generally more cross-reactive against pathogen variants than
IgG and other classes of immunoglobulins.
It has been reported that intraperitoneal administration of
OMVs derived from Salmonella typhimurium activated Salmonella-
specific T and B cell responses and elicits protective immunity
against challenge with live bacteria in mice [34]. A recent report
showed that intranasal administration of OMVs derived from V.
cholerae successfully induced protective immunity in mice [21],
although it remains unknown whether undesirable molecules such
as CT are present as containants in the OMV preparation and
whether clinical use is safe. As OMV is a cell-free antigen, its use
as a vaccine is safer than the conventional live-attenuated vaccine.
In addition, an OMV vaccine is superior to other formulations,
such as a purified protein vaccine, for economical reasons and in
terms of its stability at ambient temperature. In the present study,
we characterized the immunological properties of P. gingivalis
OMV. In conclusion, we suggest that P. gingivalis OMV might
have application as a periodontal disease vaccine. To our
knowledge, this is the first study using a combination of bacterial
OMV and Poly (I:C) for strong induction of bacterial-specific s-
IgA in saliva and nasal washes as well as IgG and IgA in serum.
Further studies will be required to examine whether this strategy
can protect against bacterial challenge and to elucidate the
mechanism of humoral immune responses to intranasal adminis-
tration of OMV.
Figure 4. Immunogenicity of OMVs and whole cells of P. gingivalis after intranasal immunization. (A) The timeline of immunization is
shown. (B–E) ELISA plates were coated with P. gingivalis whole cells. Samples of serum, nasal washes and saliva taken from mice immunized with P.
gingivalis OMV, P. gingivalis whole cells (WC), and sham-immunized (PBS) mice. P. gingivalis-specific serum IgG (B), serum IgA (C), serum IgM (D), and
nasal wash IgA (E) were examined by ELISA. For the salivary IgA (F), un-diluted saliva samples from OMV-immunized mice were compared with those
from sham-immunized (PBS) mice. The results of triplicate assays are expressed as absorbance (mean 6 SD) at 405 nm after a 30-min incubation with
alkaline phosphatase substrate. In (A) to (E), the serum and nasal wash samples were from four mice per OMV-immunized group, four mice per P.
gingivalis whole cells-immunized group (WC) and two mice per PBS control group. In (F), the saliva samples were from two PBS-immunized mice and
three OMV-immunized mice.
doi:10.1371/journal.pone.0026163.g004
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